Additional Relevant Details Thus far, we have published quite a lot around tivantinib, but we have now published and placed in the public much on our proprietary pipeline. That change is this month, but because tivantinib is the most advanced program we have, I would like to give you an update of tivantinib first. At International Liver Cancer Association ArQule investigator from Italy presented data from the Phase 2 trial of tivantinib in hepatocellular carcinoma that had been presented in several forums and published in the Lancet. Further analysis of the data supports further the underpinning on the ongoing METIV HCC Phase 3 trial. The trial is recruiting in the west of the world in collaboration with Daiichi Sankyo. This data talks to the importance of selecting patients in HCC with the biomarker we had identified in that trial. The presentations are available on our website as well as in the ILCA websites. The METIV clinical trial continued to recruit well and is well on track to be fully recruited by year end. As we had anticipated during all the calls we had this year. By year-end METIV will have enrolled just about 300 patients randomized 2:1 to receive single agent tivantinib against placebo as a second line therapy for HCC patients that are classified as MET-high. We expect a predefined interim analysis to take place during the first half of 2016, and we had discussed in different forums what the specifics of the interim analysis are.